Press Releases April 22, 2026 04:05 PM

SoundHound AI To Report 2026 First Quarter Financial Results, Host Conference Call and Webcast on May 7

SoundHound AI Announces Q1 2026 Earnings Release and Conference Call for May 7

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
SOUN

SoundHound AI, a leader in voice and conversational AI technology, will report its financial results for the first quarter of 2026 on May 7, followed by a conference call and webcast to discuss the results. The company provides AI solutions across multiple sectors including retail, financial services, healthcare, automotive, smart devices, and restaurants.

SoundHound AI To Report 2026 First Quarter Financial Results, Host Conference Call and Webcast on May 7
SOUN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • SoundHound AI will release Q1 2026 financial results on May 7, 2026, after market close.
  • The company will hold a conference call and webcast to review the results on the same day.
  • SoundHound AI delivers voice and conversational AI technology serving diverse sectors like retail, healthcare, automotive, and financial services.

SANTA CLARA, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- SoundHound AI, Inc. (Nasdaq: SOUN), a global leader in voice and conversational AI, today announced that it will report its 2026 first quarter financial results on Thursday, May 7, 2026 after market close. The company will host a conference call and webcast to review the results on the same day.

Conference Call and Webcast Information

SoundHound AI will host its conference call at 2:00 p.m. PT / 5:00 p.m. ET. A live audio webcast will be available at investors.soundhound.com and a replay will be available at the same location.

If you wish to receive company email notifications, please register at https://investors.soundhound.com/ir-resources/email-alerts

About SoundHound AI
SoundHound AI (Nasdaq: SOUN), a global leader in voice and conversational AI, delivers solutions that allow businesses to offer superior experiences to their customers. Built on proprietary technology, SoundHound’s voice AI delivers best-in-class speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants. The company’s groundbreaking AI-driven products include Smart Answering, Smart Ordering, Dynamic Drive-Thru, and the Amelia Platform, which powers AI Agents for enterprise. In addition, SoundHound’s Agentic AI for Automotive and Autonomics, a category-leading operations platform that automates IT processes, have enabled SoundHound to power millions of products and services, and process billions of interactions each year for world-class businesses.

For more information, visit: www.soundhound.com.

Investors:
Scott Smith
408-724-1498
[email protected] 

Media:
Fiona McEvoy
415-610-6590
[email protected] 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c9de3685-42dc-4886-af0e-ba6a91e710db


Risks

  • Financial results could disappoint investor expectations, impacting stock price.
  • Market adoption rates and competition in the AI and voice technology industry present uncertainty.
  • Operational risks related to scaling AI solutions across various industries may affect performance.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026